Synovial Fluid Bank From Arthritic Patients
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Establishment of a Bank of Synovial Fluids and Paired Sera From Arthritic Patients for the Evaluation of New Methods Facilitating the Diagnosis and the Monitoring of Progression and Therapy of Arthritis.|
- Availability of paired synovial fluid and serum samples for exploratory studies [ Time Frame: Use with various collaborators at different times, upon request and approbation ]Availability of paired synovial fluid and serum samples, linked with anonymized clinical and treatment data, from patients suffering from various arthritides (rheumatoid arthritis, gout and other microcrystalline arthritides, osteoarthritis, spondylarthropathies, juvenile idiopathic arthritis, and various other diseases, including inflammatory polyarthritis of recent-onset in adults
Biospecimen Retention: Samples Without DNA
|Study Start Date:||June 2002|
|Estimated Study Completion Date:||September 2029|
|Estimated Primary Completion Date:||December 2019 (Final data collection date for primary outcome measure)|
Our group has developed interdisciplinary expertise in biomarkers related to distinct aspects of inflammation-induced joint damage, most notably those associated with degradation of components of the extracellular matrix, bone loss, or associated with post-translational changes on protease inhibitors.
The objectives of this group project is to collect SF and paired sera and carry out preclinical studies to evaluate, alone or by combination testings, the potential of novel biomarkers for their prevalence and diagnostic/prognostic values in patients with arthritis, and to determine how therapeutic intervention regulate their levels.
More specifically, we will study (1) biomarkers associated with osteoclastic bone resorption and synthesis/degradation of cartilage, (2) inhibitors of enzymes (calpastatin) that are preferentially targeted by rheumatoid patients, as well as (3) enzymes (e.g. Matrix Metalloproteinases (MMPs)) responsible for the cleavage of components of the articular cartilage.
Finally, we propose to characterize the repertoire of specific active proteases in the SF of arthritic patients concomitantly to the use biomarkers (neoepitopes of cleaved collagens) previously associated with cartilage destruction and synthesis to identify new targets for the development of protease inhibitors for the treatment of arthritis. Furthermore, our project will also provide the opportunity to test the potential of measuring the net proteolytic activity by Fluorescent-Activated Substrate Conversion as a method of monitoring disease activity and treatment efficiency in a clinical setting.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00512343
|Contact: Gilles Boire, MD, MSc||(819) 564-5261||Gilles.Boire@USherbrooke.ca|
|Centre hospitalier universitaire de Sherbrooke||Recruiting|
|Sherbrooke, Quebec, Canada, J1H 5N4|
|Contact: Gilles Boire, MD, MSc (819) 564-5261 Gilles.Boire@USherbrooke.ca|
|Principal Investigator: Gilles Boire, MD, MSc|
|Principal Investigator:||Gilles Boire, MD, MSc||CHUS and Université de Sherbrooke|